Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield Iowa Jublia Coverage | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.02.00

    Jublia and Tavaborole

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.02.00 alerts

    Get alerted when Policy 05.02.00 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Jublia (efinaconazole) and generic tavaborole topical treatment of toenail onychomycosis when clinical, laboratory, treatment-failure, and noncosmetic-use criteria are met.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyJublia and Tavaborole
    Policy CodePolicy 05.02.00
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit laboratory confirmation of toenail onychomycosis and fungal etiology to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    48 weeksMaximum treatment duration
    1Lifetime approval limit
    ≤50%Maximum target-nail involvement
    4 mL/30 daysJublia quantity limit
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oral therapies required

    Medical Necessity and Exclusions

    Initial therapy

    Jublia and generic tavaborole topical treatment may be considered medically necessary when ALL of the following criteria are met.

    Approval criteria: The patient has distal lateral subungual onychomycosis of the toenail with confirmed fungal etiology; clinical involvement of the target toenail(s) is 50% or less with no lunula involvement or dermatophytomas; treatment is requested for a medical condition and not for cosmetic purposes; the patient has documented failure or contraindication to both oral terbinafine and oral itraconazole; treatment is intended as monotherapy and not combined with oral treatment; and the patient has experienced an inadequate response, adverse event, intolerance, or contraindication to a 48-week course of generic ciclopirox despite good adherence.≤50% clinical involvement; 48-week ciclopirox course

    Approval is limited to 48 weeks, with only one approval allowed in a lifetime.

    Not medically necessary

    Jublia and generic tavaborole are not medically necessary when the approval criteria are not met.

    Not medically necessary: The patient fails to satisfy one or more required approval criteria, or treatment is requested for cosmetic purposes.

    Treatment requested for cosmetic purposes is excluded from medically necessary coverage. Coverage requires that treatment be requested for a medical condition rather than cosmetic improvement.

    Jublia or generic tavaborole must be used as monotherapy. Treatment combined with oral antifungal therapy is not eligible for coverage.

    Jublia and generic tavaborole are considered not medically necessary when the stated approval criteria are not met.

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Jublia (efinaconazole) and generic tavaborole. Submit documentation supporting the diagnosis, fungal etiology, clinical eligibility, required treatment history, and medical—not cosmetic—need.

    • Requested drug: Jublia (efinaconazole) or generic tavaborole topical treatment.
    • Include laboratory confirmation, target-toenail findings, prior treatment history, and contraindications or adverse events as applicable.
    Step Therapy

    Document Ciclopirox Trial

    Document an inadequate response, adverse event, intolerance, or contraindication to a 48-week course of generic ciclopirox, despite good adherence.

    • The ciclopirox trial must be documented before approval of Jublia or generic tavaborole, unless a contraindication, intolerance, adverse event, or inadequate response is documented.

    Policy Background

    Onychomycosis is a fungal infection of the nail. Jublia (efinaconazole) and tavaborole are topical treatments indicated for toenail onychomycosis caused by Trichophyton rubrum and Trichophyton mentagrophytes. The policy uses laboratory confirmation, limited toenail involvement, and prior treatment history to identify cases in which topical therapy is medically necessary.

    Clinical Definitions

    Onychomycosis
    DefinitionA fungal infection of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes.
    Covered presentationDistal lateral subungual onychomycosis of the toenail.
    Clinical extentThe target toenail(s) must have 50% or less clinical involvement, with no lunula involvement or dermatophytomas.
    Distal lateral subungual onychomycosis
    Infection siteThe infection begins at the distal or lateral portion of the toenail.
    PatternThe infection extends beneath the nail plate.
    Covered diagnosis

    Initial Therapy

    Initial therapy criteria

    Jublia and generic tavaborole topical treatment may be considered medically necessary when ALL of the following criteria are met.

    Approval criteria

    • Diagnosis and disease extent: Diagnosis is distal lateral subungual onychomycosis of the toenail, and fungal etiology has been confirmed by appropriate laboratory testing, such as a positive potassium hydroxide (KOH) stain, fungal culture, or nail biopsy.
    • Target toenail involvement: Clinical involvement of the target toenail(s) is 50% or less, with no lunula involvement or dermatophytomas present.≤50% clinical involvement
    • Medical necessity: Treatment is requested due to a medical condition and not for cosmetic purposes.

    Continuation Therapy

    No continuation approval

    Continuation therapy is not approvable.

    Continuation limitation: Only one 48-week approval is allowed in a patient's lifetime.48 weeks; 1 lifetime approval

    No continuation approval is available.

    Required Treatment History

    StepPrior therapy requirementRequired outcome
    1Trial of generically available ciclopirox before Jublia or tavaboroleA 48-week course must have resulted in an inadequate response, adverse event, intolerance, or contraindication despite good adherence.
    StepPrior therapy requirementRequired outcome
    2Both oral terbinafine and oral itraconazole must have been tried or be contraindicated.Documented failure or contraindication to both oral therapies.

    Drug Quantity Limits

    Jublia quantity limit
    DrugJublia (efinaconazole topical solution, 10%).
    Quantity limit4 mL per 30 days.
    Billing periodThe limit applies to each 30-day period.
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyJublia and Tavaborole
    Policy CodePolicy 05.02.00
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit laboratory confirmation of toenail onychomycosis and fungal etiology to initiate prior authorization review.
    SourceLink
    On This Page
    Medical Necessity and ExclusionsPrior Authorization and DocumentationPolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyRequired Treatment HistoryDrug Quantity Limits
    Step Therapy

    Address Both Oral Antifungal Alternatives

    Document failure of or a contraindication to both oral antifungal alternatives: terbinafine and itraconazole.

    • Documentation must address both oral therapies—not just one.
    • Explain the treatment failure, adverse event, intolerance, or contraindication for each agent, as applicable.
    Documentation Required

    Submit Laboratory Confirmation

    Submit laboratory testing confirming onychomycosis and the fungal etiology.

    • Acceptable examples include a positive potassium hydroxide (KOH) stain, fungal culture, or nail biopsy.
    Documentation Required

    Document Clinical Eligibility

    Document that the patient has distal lateral subungual onychomycosis of the toenail with 50% or less clinical involvement of the target toenail(s), without lunula involvement or dermatophytomas. Also document that treatment is medically necessary, requested as monotherapy, and not intended for cosmetic purposes.

    • The condition should be due to Trichophyton rubrum or Trichophyton mentagrophytes.
    • Explain the medical need, such as immunocompromised status, history of lower-extremity cellulitis, diabetes with additional cellulitis risk factors, or extensive nail involvement causing severe pain or limited ambulation.
    • Confirm treatment will not be combined with oral antifungal therapy.
    Denial Risk

    Denial Risk: Incomplete Criteria

    Requests may be denied when required clinical, laboratory, or prior-treatment criteria are absent or cannot be verified.

    • Missing fungal confirmation, target-toenail findings, medical-necessity rationale, ciclopirox trial documentation, or failure or contraindication to both terbinafine and itraconazole may result in denial.
    • Jublia and generic tavaborole are not medically necessary when the stated approval criteria are not met.
    Denial Risk

    Denial Risk: Cosmetic Use

    Treatment requested solely to improve nail appearance is not eligible for approval.

    • Document a qualifying medical condition or clinical risk—not cosmetic concerns—as the reason for treatment.
    Billing Rule

    Lifetime Limit on Approval

    Approval is limited to one 48-week course during the patient's lifetime. Continuation or repeat therapy is not approvable.

    • Request treatment as a single 48-week course.
    • Do not submit a continuation request after the lifetime approval has been used.
    Distal lateral subungual onychomycosis of the toenail is the covered infection pattern.
    Confirmed fungal etiology
    KOH stainA positive potassium hydroxide (KOH) stain.
    Fungal cultureA positive fungal culture.
    Nail biopsyNail biopsy confirming fungal infection.

    Examples include immunocompromised patients; patients with a history of lower-extremity cellulitis; patients with diabetes and additional risk factors for cellulitis; or patients with extensive nail involvement resulting in severe pain or limits to ambulation.

  1. Prior oral therapy: The patient has a documented failure with or contraindication to both oral therapies: terbinafine and itraconazole.

    Both oral therapies must be addressed.

  2. Prior ciclopirox therapy: The patient has experienced an inadequate response, adverse event, intolerance, or contraindication to a 48-week treatment course of generically available ciclopirox despite good adherence.48-week course
  3. Treatment regimen: Treatment is intended as monotherapy and will not be combined with oral treatment.Monotherapy